Article

PREDICTIVE IMMUNE CHECKPOINT BLOCKADE CLASSIFIERS DISTINGUISHING MONO- VERSUS COMBINATION THERAPY REQUIREMENT

2020-07-15

Abstract excerpt

Although high clinical response rates are seen for immune checkpoint blockade (ICB) treatment of metastatic melanomas, both intrinsic and acquired ICB resistance remain considerable clinical challenges 1 . Combination ICB (anti-PD-1 + anti-CTLA-4) shows improved patient benefit 2–5 , but is associated with severe adverse events and exceedingly high cost. Therefore, there is a dire need to stratify individual pat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b2e5a24e-98ff-52f2-b3f0-0a2ca520ab75
DOI: 10.1101/2020.07.14.202408

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PREDICTIVE IMMUNE CHECKPOINT BLOCKADE CLASSIFIERS DISTINGUISHING MONO- VERSUS COMBINATION THERAPY REQUIREMENTDOI 10.1101/2020.07.14.202408Read

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaSemantic proximity Read

Integrated germline and somatic features reveal divergent immune pathways driving ICB responseSemantic proximity Read

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.Semantic proximity Read

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response RatesSemantic proximity Read

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.Semantic proximity Read

Immunogenic cell death signatures derived from on-treatment tumor specimens for predicting immune checkpoint blockade therapy response and prognosis in metastatic melanomaSemantic proximity Read

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaSemantic proximity Read

A Conserved Landscape of Chemokine Receptor Co-expression Defines the Functional States of CD8+ T Cells in MelanomaSemantic proximity Read

Tumor Immune Cell Infiltration Patterns and Predictable Clinical Benefit with Nivolumab in Combination with Ipilimumab for 3P ImplementationSemantic proximity Read

Transcriptional analysis of immune modulatory genes in melanoma treated with PD-1 blockadeSemantic proximity Read

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.Semantic proximity Read

Strategies for Improving the Performance of Prediction Models for Response to Immune Checkpoint Blockade Therapy in CancerSemantic proximity Read